anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present disclosure is related to a group of alkamides with important analgesic activity and its use in the treatment of neuropathic and dental pain. Emphasizing their simple and economical synthesis methods. In the present invention, the following is demonstrated: its analgesic activity, its action mechanism through the signaling pathways of TRPV1, GABA and cannabinoids, as well as its innocuousness. Highlighting the results obtained, which demonstrate the nonexistence of pungency and irritability, the nonexistence of acute and subchronic toxicity and the nonexistence of genotoxicity. As well as its inability to cause seizures, an adverse effect of other analogous alkamides, which makes them ideal candidates for pharmaceutical formulations focused on providing a local effect or a systemic effect, without the use of needles for its application. Through this patent application, the following is claimed: the chemical structures, the synthesis methods, the identification method, the analgesic activity, the innocuousness, the action mechanisms and the pharmaceutical formulations.
Tatton-Brown-Rahman syndrome (TBRS) is a rare congenital genetic disorder caused by autosomal dominant pathogenic variants in the DNA methyltransferase DNMT3A gene. Typical TBRS clinical features are overgrowth, intellectual disability, and minor facial anomalies. However, since the syndrome was first described in 2014, a widening spectrum of abnormalities is being described. Cardiovascular abnormalities are less commonly reported but can be a major complication of the syndrome. This article describes a family of three individuals diagnosed with TBRS in adulthood and highlights the variable expression of cardiovascular features. A 34-year-old proband presented with progressive aortic dilatation, mitral valve (MV) regurgitation, left ventricular (LV) dilatation, and ventricular arrhythmias. The affected family members (mother and brother) were diagnosed with MV regurgitation, LV dilatation, and arrhythmias. Exome sequencing and computational protein analysis suggested that the novel familial DNMT3A mutation Ser775Tyr is located in the methyltransferase domain, however, distant from the active site or DNA-binding loops. Nevertheless, this bulky substitution may have a significant effect on DNMT3A protein structure, dynamics, and function. Analysis of peripheral blood cfDNA and transcriptome showed shortened mononucleosome fragments and altered gene expression in a number of genes related to cardiovascular health and of yet undescribed function, including several lncRNAs. This highlights the importance of epigenetic regulation by DNMT3A on cardiovascular system development and function. From the clinical perspective, we suggest that new patients diagnosed with congenital DNMT3A variants and TBRS require close examination and follow-up for aortic dilatation and valvular disease because these conditions can progress rapidly. Moreover, personalized treatments, based on the specific DNMT3A variants and the different pathways of their function loss, can be envisioned in the future.
FIELD: medicine, pulmonology, pharmacology, pharmacy. SUBSTANCE: invention relates to the use of formoterol and budesonide in treatment of chronic obstructive lung disease. Invention claims also set for treatment and method of treatment using indicated combination. The proposed agent is more effective. Treatment method allows to diminish intensity of disease exacerbations. EFFECT: enhanced effectiveness of agent and treatment. 10 cl
1334732 Coated tablets SCHERICO Ltd 5 Jan 1971 [6 Jan 1970] 448/71 Heading A5B A pharmaceutical tablet comprises a core surrounded by layers containing medicament and between two medicament layers a layer comprising 10-50 weight % of silica gel having an average pore diameter of 90-400 Angstroms. The medicament layers may be surrounded by further outer coating layers. Similar porous silica gel layers may be present between the core and the medicament layers, between the medicament and coating layers and/or between two coating layers. The medicament in the layers may be phenylephrine or phenylephrine hydrochloride. The core may also include a medicament. The tablet is made by applying successive coatings to the core and drying the coated core at elevated temperature. The silica gel layer may be applied as powder or slurry. In an Example, a composition consisting of phenacetin, caffeine, starch and gelatin solution is formed into granules by the wet granulation method. The granules are mixed with calcium stearate, aspirin and more starch and compressed into cores. The cores are coated with (a) a composition comprising sugar, acacia and water, (b) a powder consisting of silica gel and terra alba (CaSO 4 ), (c)-(l) a suspension consisting of chloropheniramine maleate, L-phenylephrine, sugar, acacia and water alternating with the silica gel/terra alba powder, (m)-(o) three coats of a composition consisting of silical gel, terra alba, titanium dioxide, corn starch and water and (p) titanium dioxide suspended in sugar syrup. The tablet is dried after each coating of silica gel/terra alba powder.
OBJECTIVES: Recent studies have increasingly demonstrated that a multiplatform water environment combined with lard gavage is an effective method for establishing a mouse model of diarrhea. However, the interactions between intestinal microorganisms and diarrhea, as well as the relationships among energy metabolism, fluid balance, and gastrointestinal function in this model, remain poorly understood.
METHODS: Building on previous research, this study aimed to optimiz and replicate a multiplatform water environment combined with a lard gavage model. Male Kunming mice, free of specific pathogens, were randomly divided into four groups: a normal control group (ZC), a standing group (ZL), a standing combined with lard group (ZLZ), and a standing combined with internal and external wet conditions group (ZLZS). The mice in the ZL, ZLZ, and ZLZS groups were subjected to 4 hours of daily standing in a custom-designed multiplatform water environment. Starting on day 8, mice in the ZLZ and ZLZS groups were gavaged with lard (0.4 mL per session, twice daily) for 7 consecutive days, while those in the ZLZS group were additionally exposed to a wet litter environment (50 g/100 mL). The ZC and ZL groups received equal volumes of sterile water via gavage. The microbiota in the small intestine, as well as serum levels of cAMP, cGMP, VIP, Gas, and D-xylose, were analyzed.
RESULTS: Compared with the ZLZ group, the ZLZS group showed significantly lower serum levels of cAMP/cGMP (p<0.01) and Gas (p<0.01). D-xylose levels were lower in the ZL, ZLZ, and ZLZS groups compared to the ZC group, while VIP levels were significantly higher in the ZL and ZLZS groups (p<0.01). Moverover, Corynebacterium, Empedobacter, and Pseudochrobactrum were identified as characteristic bacterial genera in the ZLZS group. The mechanism by which the small intestinal microbiota induces diarrhea was linked to the biosynthesis of secondary bile acids.
CONCLUSION: A multiplatform water environment combined with lard gavage can effectively induce diarrhea, and the addition of an external wet environment exacerbates this condition by affecting small intestinal contents microbiota and other functions.
In addition to conventional chest physiotherapy programme, patients in this group will also receive BreathingLabs Breathing Games based exercise training for 40 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised by physiotherapist in a clinic per week.
Basal cell carcinoma (BCC) is the most common skin cancer in the world, with approximately 3.5 million cases a year diagnosed in the United States. BCC are indolent and metastasis is extremely rare, occurring in less than .003% of cases. However, due to the high prevalence of this tumor, significant health care resources are used in its diagnosis and treatment. Management of BCC in many instances includes clinical evaluation of the lesion, biopsy or sampling of the lesion to confirm the diagnosis, followed by definitive treatment at a later date through surgical excision or medical therapy. A clinical diagnosis of BCC can be made with a high degree of confidence based on clinical findings. The investigators propose that by performing a deep shave removal of the entire lesion with histologically negative margins, based upon clinical diagnosis, complete removal can be achieved without the need for follow up therapy. Deep shave removal at time of initial evaluation is performed in many instances. The investigators believe that doing a deep shave removal would substantially reduce the number of second procedures that need to be done, thereby reducing treatment costs and patients' need to return for an additional procedure. In doing a deep shave removal, clinically diagnosed BCC will be removed entirely with narrow 2-3 mm margins, the tissue specimen will then be sent to the pathologist to confirm that margins are clear. The investigators will consider treatment of the BCC to be complete at this point and will follow the patients clinically.
<P>PROBLEM TO BE SOLVED: To provide a hair-growing agent having the hair-growing effects equal to or larger than those of a conventional hair-growing agent including a large amount of 40-50 wt.% of comparatively expensive powdered tourmaline ore in a product of a viscous material by a smaller content of the tourmaline ore from economical viewpoint.  <P>SOLUTION: The hair-growing agent is obtained by, at first, using the fine powder obtained by further finely pulverizing a 325 mesh-pass powder of the lithia tourmaline ore to make the maximum diameter ≤10 μm. The result is considered to be obtained by elongating the holding time of the tourmaline on the skin of the head part, and heightening the activation effects of the skin of the head part. The dispersibility of the fine powder and the viscous material of the product having well stabilized homogeneity are improved by the use of a high-viscosity polyethylene glycol-240, sodium hyaluronate or the like, and the content of the tourmaline fine powder can be reduced to 2-7 pts.wt. by adding an essence of Panax ginseng and an essence of Swertia japonica for enhancement of the hair-growing effects.  <P>COPYRIGHT: (C)2008,JPO&INPIT
This protocol is to identify and characterize distinct types of chronic orthostatic intolerance (COI). COI can be a manifestation of primary chronic autonomic failure, which is covered under a separate protocol. The present protocol concerns patients with COI who under resting conditions have intact sympathetic neurocirculatory function. COI can reflect different pathophysiologic mechanisms; until now, few studies have attempted to distinguish these mechanisms in individual patients. We hypothesize that results of clinical assessment and physiologic, chemical, pharmacologic, and imaging tests will reveal internally consistent patterns that distinguish particular forms of COI. We wish to determine the relative frequencies of these forms in a referral population. The first phase of testing is to identify sympathetic neurocirculatory failure, baroreflex failure, and secondary causes of COI (hypovolemia, excessive orthostatic venous pooling, or excessive orthostatic extravasation). In a subsequent inpatient phase, tilt table testing is done, with concurrent hemodynamic and chemical measurements, to confirm subtypes of postural tachycardia syndrome and neurocardiogenic syncope. The results of these evaluations will be used for stratification of specific, pathophysiologically defined diagnostic groups for therapeutic protocols. In an off-site study, we will evaluate members of a large family where COI seems to be transmitted as an autosomal dominant trait.
NEW MATERIAL:A 2-(alkyl-cyclohexyl)-1-propanol shown by formula I (R1 and R2 are groups selected from methyl, ethyl, n-propyl, isopropyl, t-butyl and sec-butyl, R1 and R2 have 4-7 carbons, or when R1 is H, R2 is cyclohexyl or R1 and R2 may be bonded together with two carbons on cyclohexane ring and form 6-membered ring). EXAMPLE:2-(2-Methyl-5-isopropyl-1-cyclohexyl)-1-propanol. USE:Useful as a perfume composition. Ordinary perfume is blended with 1-10wt.% of the compound as a mixing material to provide the perfume with woody and floral fragrance. Usable in perfume or soap. PREPARATION:A compound shown by formula II is reacted with propylene oxide in the presence of Lewis acid and then hydrogenated to give a compound shown by formula I.
The paravertebral block is performed under the ultrasound guidance at T7. Drug: ropivacaine 0.5% 20 ml (maximum dose \<= 3 mg/kg). Maintenance: ropivacaine 0.25% 8 ml/hour during 48 hours.
<P>PROBLEM TO BE SOLVED: To provide a method for proliferating epithelial cells or interstitial cells derived from the amnion by keeping as undifferentiated in a large amount in vitro, and the utilization of the same.  <P>SOLUTION: By culturing the epithelial cells or interstitial cells derived from the amnion in the presence of an extracellular substrate of basement membrane or an FGF, it is possible to proliferate them by keeping as undifferentiated in the large amount in vitro. Also, it is possible to maintain pluripotency after proliferating in the large amount. That is, it is possible to differentiate them to various cells by a differentiation-inducing stimulation. Also, since the cells proliferated by the culturing method have the pluripotency like an undifferentiated ES cells, they are very useful for regenerative medicine, etc.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
BACKGROUND: In 2019, the International Association for the Study of Pain introduced the concept of 'chronic primary pain (CPP)', characterized by persistent non-organic pain with emotional and functional abnormalities. Underdiagnosed and linked to depression, CPP has poorly understood neural characteristics. Electroencephalogram (EEG) microstates enable detailed examination of brain network dynamics at the millisecond level. Incorporating task-related EEG features offers a comprehensive neurophysiological signature of brain dysfunction, facilitating exploration of potential neural mechanisms.
METHODS: This study employed resting-state and task-related auditory Oddball EEG paradigm to evaluate 20 healthy controls, 20 patients with depression, and 20 patients with CPP. An 8-minute recording of resting-state EEG was conducted to identify four typical microstates (A-D). Additionally, power spectral density (PSD) features were examined during an auditory Oddball paradigm.
RESULTS: Both CPP and Major Depressive Disorder (MDD) patients exhibited reduced occurrence rate and transition probabilities of other microstates to microstate C during resting-state EEG. Furthermore, more pronounced increase in Gamma PSD was observed in the occipital region of CPP during the Oddball task. In CPP, both resting-state microstate C and task-related Gamma PSD correlated with pain and emotional indicators. Notably, microstate C occurrence positively correlated with occipital Gamma PSD in MDD.
CONCLUSION: Conclusively, both CPP and MDD display dynamic abnormalities within the salient network, closely associated with pain and depressive symptoms in CPP. Unlike MDD, CPPs' dynamic network changes appear unrelated to perceptual integration function, indicating differing microstate functional impacts. Combining resting-state microstates and Oddball tasks may offer a promising avenue for identifying potential biomarkers in objectively assessing chronic primary pain.
By recruiting native conducting tissue to relay electrical activation of the ventricles via the Purkinje fibre network, DHBP may potentially achieve greater electrical resynchronization and hemodynamic benefit compared to BiV where the electrical activation wavefronts propagate from two discrete pacing sites. Electrical synchrony achieved by these pacing modes have however never been compared. Furthermore, the acute hemodynamic effect of DHBP has been compared to BiV only in a small single study to date. The aims are to compare DHBP with BiV in terms of electrical resynchronization using electrocardiographic imaging (ECGI) and also in terms of acute hemodynamical effect using finger plethysmography and conduction velocimetry. The primary endpoint will be left ventricular activation time, with secondary endpoints including various electrical (right ventricular activation time, total ventricular activation time etc) and hemodynamic parameters (systolic pressure, cardiac output, cardiac contractility). It is expected that DHBP offers shorter left ventricular activation time (i.e. better synchrony) and hemodynamic benefit compared to BiV.
A randomized, double-blind, placebo-controlled trial of ACTIMMUNE (interferon gamma-1b) in patients with CGD, was performed to determine whether ACTIMMUNE administered subcutaneously on a three times weekly schedule could decrease the incidence of serious infectious episodes and improve existing infectious and inflammatory conditions in patients with CGD. One hundred twenty-eight eligible patients were enrolled in this trial including patients with different patterns of inheritance. Most patients received prophylactic antibiotics. Patients ranged in age from 1 to 44 years with the mean age being 14.6 years. The study was terminated early following demonstration of a highly statistically significant benefit of ACTIMMUNE therapy compared to placebo with respect to time to serious infection (p=0.0036), the primary endpoint of the investigation. Serious infection was defined as a clinical event requiring hospitalization and the use of parenteral antibiotics. The final analysis provided further support for the primary endpoint (p=0.0006). There was a 67 percent reduction in relative risk of serious infection in patients receiving ACTIMMUNE (n=63) compared to placebo (n=65). Additional supportive evidence of treatment benefit included a twofold reduction in the number of primary serious infections in the ACTIMMUNE group (30 on placebo versus 14 on ACTIMMUNE, p=0.002) and the total number and rate of serious infections including recurrent events (56 on placebo versus 20 on ACTIMMUNE, p=<0.0001). Moreover, the length of hospitalization for the treatment of all clinical events provided evidence highly supportive of an ACTIMMUNE treatment benefit. Placebo patients required three times as many inpatient hospitalization days for treatment of clinical events compared to patients receiving ACTIMMUNE (1493 versus 497 total days, p=0.02). An ACTIMMUNE treatment benefit with respect to time to serious infection was consistently demonstrated in all subgroup analyses according to stratification factors, including pattern of inheritance, use of prophylactic antibiotics, as well as age. There was a 67 percent reduction in relative risk of serious infection in patients receiving ACTIMMUNE compared to placebo across all groups. The beneficial effect of ACTIMMUNE therapy was observed throughout the entire study, in which the mean duration of ACTIMMUNE administration was 8.9 months/patient.
Before the first application of the day, the "12-Item Itching Severity Scale" will be applied to evaluate the patient's daily itching. Before each application, the Visual Analog Scale (VAS) for Itch will be shown at minute 0 and they will be asked to evaluate the severity of itching they feel immediately. Vital signs will be measured and recorded. Liquid petroleum jelly, which is the routine practice of the clinic, will be applied by clinic nurses. Immediately after the application is completed, a 20-minute VAS for itching will be shown and they will be asked to evaluate the severity of itching they feel immediately.
BACKGROUND: The association of sarcopenia and frailty syndrome with dietary patterns is not yet well recognized.
THE AIM: The aim of the study was to evaluate the association among dietary patterns, suspected sarcopenia, and frailty syndrome among older people in Poland.
METHODS: The study was conducted in 2022 and 2023 among people aged 55 and older. The sample was chosen arbitrarily. The following questionnaires were used in the study: the KomPAN (assessment of frequency of food intake and sociodemographic characteristics), the SARC-F (assessment of risk of sarcopenia), and the EFS (diagnosis of frailty syndrome). To confirm the suspicion of sarcopenia, muscle strength was assessed using the HGS and FTSST, and physical fitness was assessed using the GST. Based on the frequency of food consumption, 11 DPs (factors) were selected using PCA analysis. SARC-F, HGS, FTSST, and GST results were used to identify homogeneous groups (clusters) using cluster analysis, a k-means method.
RESULTS: Two clusters were identified: cluster 1 (the non-sarcopenic cluster, or nSC) and cluster 2 (the sarcopenic cluster, or SC). Associations between variables were assessed using logistic regression. Suspected sarcopenia was found in 32.0% of respondents, more in men than women, and more among those either over 75 or 65 and under. EFS results showed that the risk (22.1%) or presence of frailty syndrome (23.8%) was more common in men than women and more common in those aged 75 and older than in other age groups. Male gender; older age; and unfavorable dietary patterns, i.e., consumption of white bread and bakery products, white rice and pasta, butter, and potatoes (factor 1) and cheese, cured meat, smoked sausages, and hot dogs (factor 9), increased the likelihood of sarcopenia and frailty syndrome, while the pattern associated with fruit and water consumption (factor 7) had the opposite effect.
CONCLUSIONS: Confirmation of the importance of dietary patterns in the etiology and pathogenesis of sarcopenia and frailty syndrome should be documented in prospective cohort studies.
A total of 100 healthy adults, pre-screened to be negative for anti-dengue antibodies will be enrolled upon written informed consent. 75 subjects in the test arm will received 2 doses of inactivated Japanese Encephalitis vaccine and 1 dose of Yellow Fever vaccine.
The invention relates to a scar improving technology, in particular to a silk fibroin micro-needle patch for improving hypertrophic scars and a preparation method thereof. The invention aims to provide a new choice for improving scars. The silk fibroin microneedle patch for improving hypertrophic scars comprises a back lining layer and microneedles distributed on the back lining layer in an array mode, wherein the density of the microneedle array is 10-250 microneedles/cm 2 The needle body is in a quadrangular pyramid shape or a conical shape, and the height of the needle is 600-1000 mu m; the microneedle is prepared by taking silk fibroin as a raw material. The microneedle patch has good biocompatibility, slowly degrades in scar tissues, continuously plays a role in physical intervention and realizes the improvement of hypertrophic scarsThe purpose is. The microneedle patch does not contain any hormone or other drugs, and has high biological safety. And the scar-removing device has the characteristics of minimally invasive painlessness and convenience in use, can be used by patients, and greatly improves the self-management of scar patients.